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Macrophages are the primary immune cells that reside within the myocardium, suggesting 
that these mononuclear phagocytes are essential in the orchestration of cardiac immunity 
and homeostasis. Independent of the nature of the injury, the heart triggers leukocyte 
activation and recruitment. However, inflammation is harmful to this vital terminally dif-
ferentiated organ with extremely poor regenerative capacity. As such, cardiac tissue has 
evolved particular strategies to increase the stress tolerance and minimize the impact of 
inflammation. In this sense, growing evidences show that mononuclear phagocytic cells 
are particularly dynamic during cardiac inflammation or infection and would actively par-
ticipate in tissue repair and functional recovery. They respond to soluble mediators such 
as metabolites or cytokines, which play central roles in the timing of the intrinsic cardiac 
stress response. During myocardial infarction two distinct phases of monocyte influx 
have been identified. Upon infarction, the heart modulates its chemokine expression 
profile that sequentially and actively recruits inflammatory monocytes, first, and healing 
monocytes, later. In the same way, a sudden switch from inflammatory macrophages 
(with microbicidal effectors) toward anti-inflammatory macrophages occurs within the 
myocardium very shortly after infection with Trypanosoma cruzi, the causal agent of 
Chagas cardiomyopathy. While in sterile injury, healing response is necessary to stop 
tissue damage; during an intracellular infection, the anti-inflammatory milieu in infected 
hearts would promote microbial persistence. The balance of mononuclear phagocytic 
cells seems to be also dynamic in atherosclerosis influencing plaque initiation and fate. 
This review summarizes the participation of mononuclear phagocyte system in cardio-
vascular diseases, keeping in mind that the immune system evolved to promote the 
reestablishment of tissue homeostasis following infection/injury, and that the effects of 
different mediators could modulate the magnitude and quality of the immune response. 
The knowledge of the effects triggered by diverse mediators would serve to identify new 
therapeutic targets in different cardiovascular pathologies.
Keywords: macrophages, monocytes, Chagas disease, atherosclerosis, oxidative stress, interleukin-6, oxidized 
phospholipids, purinergic signaling
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iNTRODUCTiON
Cardiovascular diseases are the leading causes of worldwide 
morbidity and mortality. In consequence, understanding the pre-
cise contribution of the mechanisms involved in cardiovascular 
tissue injury and repair is of prominent importance. In this sense, 
increasing evidences reveal that innate immune response plays a 
critical and complex role throughout the acute inflammation and 
regenerative process triggered after cardiac or vascular injury. As 
such, leukocytosis and monocytosis have been associated with 
cardiovascular diseases in numerous epidemiological studies, 
prompting speculation on the functional importance of these cells 
(1). The goal of this review is to summarize the complex immu-
nobiology of mononuclear phagocytic cells and their relevance 
to the pathogenesis of cardiovascular diseases, highlighting the 
effect of major immune modulators.
Origin
In the last decade, important advances in the knowledge of mac-
rophage origin have triggered an essential conceptual progress in 
the mononuclear phagocyte system field. Parabiosed mice and 
genetic fate-mapping experiments have revealed that the majority 
of resident macrophages in healthy tissues are established from the 
yolk sac and fetal liver before birth (2–4). This cellular compart-
ment locally self-maintains throughout life within the tissue and 
is independent from the hematopoietic input. On the other hand, 
during adulthood tissue-infiltrating macrophages can develop 
from circulating monocytes. The recruitment of monocytes is 
associated with pathological, but also with homeostatic response. 
Macrophages derived from monocytes display a short lifespan, 
although exceptions have also been reported. Embryonic- and 
adult-derived macrophages generally coexist in a given tissue, and 
their respective number correlates with the origin and records of 
their tissue of residence. Seminal experiments have demonstrated 
that embryonic- and monocyte-derived macrophages make 
different functional contributions in homeostatic conditions or 
following challenge. In this sense, Levine and coworkers have 
revealed that embryonic-derived macrophages are clue for car-
diac recovery after injury (5). Their results suggest that targeting 
specific macrophage lineages could have important therapeutic 
implications in order to improve treatments for heart diseases.
Adult resident macrophage compartments seem to be inde-
pendent from monocyte recruitment in a given tissue, as was dem-
onstrated by parabiotic experiments. Monocyte compartments 
of the parabionts reach, with time, considerable chimerism in 
the joined circulation. However, tissue macrophages failed to 
equilibrate even after several months of parabiosis, suggesting the 
absence of an ongoing steady-state contribution of bone marrow-
derived cells to adult tissue macrophage compartments (3). 
Furthermore, recruited monocytes are short-lived effector cells 
in tissues and assumed different roles that have yet to be better 
defined; emerging reports suggest, for example, that monocytes 
can promote angiogenesis and arteriogenesis (6). In addition, 
it was recently reported that inflammatory Ly6Chigh monocytes 
persist during the steady state without commitment toward mac-
rophage or dendritic cell (DC) fates and might contribute to anti-
gen transport toward lymph nodes (7). Remarkably, macrophage 
effector function also needs to be tailored to its tissue of residence, 
an adaptation that is driven by the local microenvironment and 
by the inflammatory history of a given tissue.
Phenotypes and Functions of Monocytes
Monocytes/macrophages are very plastic cells and can acquire 
distinct phenotypes and activation states under the influence 
of different microenvironments. Although several authors have 
shown that macrophages treated with different stimuli display 
altered phenotypes or functional capacities, many of these stud-
ies are limited considering that they compare only one particular 
activation state with non-polarized macrophages. Although 
macrophage activation was initially seen as a dichotomy between 
classically and alternatively activated states, it is now clear that 
the spectrum of macrophage activation states is much more 
diverse.
Monocytes develop in steady state in the bone marrow from 
hematopoietic precursors, and they enter the circulation via 
CCR2 receptor. In mice, circulating monocytes are phenotypically 
and functionally heterogeneous and can be defined according to 
Ly6C expression marker (Figure 1). In mice, during steady-state 
conditions, about 50–60% of circulating monocytes belongs to 
the Ly6Chigh CCR2high CX3CR1low CD62L+ subset. These inflam-
matory or classical monocytes have a relatively short-circulating 
lifespan and are preferentially recruited to injured/inflamed 
tissues where they maturate to macrophages. The remaining non 
classical (Ly6Clow CCR2low CX3CR1high CD62L−) subset patrols 
blood vessels and accumulates at low numbers in the steady 
state (8). The number of Ly6Chigh monocytes rises during inflam-
mation, at expenses of enhanced monocytopoiesis in the bone 
marrow and spleen (1, 9–11). Regarding the origin, evidence 
shows that monocyte subpopulations do not arise from separate 
progenitors, but rather convert from the Ly6Chigh to Ly6Clow subset 
(12) (Figure 1).
In humans, circulating monocytes can be segregated into 
three major subsets based on the expression of CD14 and CD16 
(13). Over the past decades, human circulating monocytes had 
been separated into two subpopulations based on CD16 expres-
sion, the CD14+  CD16− and CD14+ CD16+ monocyte subsets 
(hereby designated as CD16− and CD16+, respectively). A new 
nomenclature defines three monocyte populations, where the 
minor CD16+ subset is further separated into two subpopulations 
(Figure 2). The intermediate subset expresses relatively high lev-
els of CD14 coupled with low CD16 expression (CD14++ CD16+), 
while the non-classical subset expresses low levels of CD14 with 
Abbreviations: AGE, advanced glycation end-products; APCP, adenosine 
5′α,β-methylene-diphosphate; CCR2, chemokine (C–C motif) receptor 2; 
CD39, ectonucleoside triphosphate diphosphohydrolase-1 enzyme; CD73, ecto-
5′-nucleotidase enzyme; CVB3, enteroviral coxsackievirus B group type 3; DC, 
dendritic cells; HMGB1, high-mobility group box-1 protein; IL, interleukin; iNOS, 
inducible nitric oxide synthase; KO, knock out; LDL, low-density lipoprotein; 
LDLR, low-density lipoprotein receptor; Ly6C, lymphocyte antigen 6 complex; 
Mhem, hemorrhage-associated macrophages; NADPH, nicotinamide adenine 
dinucleotide phosphate; NF-κB, pro-inflammatory signaling pathways; NO, nitric 
oxide; NO2-FAs, nitro-fatty acids; oxLDL, oxidized low-density lipoprotein; oxPL, 
oxidized phospholipids; PBMC, peripheral blood mononuclear cells; PKM2, 
pyruvate kinase M2; PRRs, pattern-recognition receptor; RONS, reactive oxygen 
and nitrogen species; SR, scavenger receptor; TLR, toll-like receptor; WHO, World 
Health Organization.
FiGURe 1 | Murine monocyte and macrophage subsets. Murine monocytes 
develop from a common myeloid progenitor and leave the bone marrow 
through the chemokine receptor CCR2. In bloodstream, circulating 
monocytes are phenotypically and functionally heterogeneous. Non-classical 
monocytes (Ly6Clow CCR2low CX3CR1high CD62L−) patrol the vasculature and 
accumulate at low numbers in the steady state. Inflammatory or classical 
(Ly6Chigh CCR2high CX3CR1low CD62L+) monocytes have a relatively 
short-circulating lifespan and preferentially accumulate in inflammatory sites 
where they give rise to inflammatory M1 macrophages (F4/80+ CD11b+ 
CD86+ CD206−). M1 macrophage subset has high microbicidal capacity due 
to their ability to produce inflammatory cytokines [TNF, IL-1β], reactive oxygen 
species (ROS) secretion and the expression of iNOS enzyme that 
metabolizes arginine to arginine-derived killer molecule NO. Non-classical 
monocytes can be recruited to tissue and differentiate to M2 macrophages 
(F4/80+ CD11b+ CD86− CD206+), which secrete anti-inflammatory cytokines 
(IL-10, IL-4) and contribute to tissue repair mechanisms.
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high expression of CD16 (CD14+ CD16++). The subset with high 
CD14 and no CD16 expression, termed classical subset (CD14++ 
CD16−), constitute approximately 85–90% of human monocytes 
in the peripheral blood. Several studies have demonstrated that 
circulating CD16+ monocytes are found in large numbers in 
patients with inflammation processes (14) and infectious diseases 
(15, 16).
Analyses based on hierarchical clustering of gene expression 
profiles of human monocyte subsets have been a matter of debate. 
Cros et al. reported that the classical and intermediate subpopu-
lations were most closely related among the subsets, while the 
most distant was the non-classical subset (17). However, other 
independent groups described that both CD16+ subpopulations 
are more closely related (18, 19). Indeed, the number of genes 
that were significantly different between both CD16+ subsets was 
the lowest among the three subpopulations. Until now, there is 
poor agreement on the effector functions of the three monocyte 
subsets. In this sense, it was reported that TNF is produced 
mainly by CD16+ monocytes (intermediate and non-classical 
subsets) (20, 21). However, recent results have evidenced that 
TNF is produced by the three subsets. While Cros et  al. (17) 
described that non-classical monocytes were poor producers of 
several cytokines [TNF, interleukin (IL)-1β, CCL2, IL-10, IL-8, 
IL-6, and CCL3] in response to LPS, other reports showed that 
the stimulation of intermediate subset with LPS produced the 
most TNF, IL-1β, and IL-6. In agreement, others also showed that 
intermediate monocytes produced the most TNF and IL-1β upon 
treatment with LPS and that this subset is the highest producer of 
TNF when cocultured with pre-activated T cells (22). In addition, 
Wong et al. (18) showed that non-classical monocytes upon LPS 
stimulation produced the highest levels of TNF and IL-1β, while 
equivalent amounts of IL-6 and IL-8 were produced by all three 
subsets. Other reports also recognized non-classical monocyte 
population as the greatest producer of TNF (21). Hence, it seems 
that non-classical monocytes constitute the subset capable of 
producing inflammatory cytokines in response to TLR ligands. 
There are also controversies on which monocyte subset is the 
major producer of the anti-inflammatory cytokine IL-10. In this 
sense, although it was demonstrated that intermediate monocytes 
produced the most IL-10 in response to LPS and zymosan (23), 
some recent reports showed that classical monocytes produced 
the most IL-10 (17, 18, 24). Further studies are necessary to 
clarify this relevant question.
Phenotypes and Functions of 
Macrophages
Several studies on macrophage biology have focused on the 
particular functions that these cells acquire after tissue accumula-
tion. Macrophages are highly plastic and can adapt to environ-
mental stimuli, displaying either a classically activated (M1) or 
alternatively activated (M2) profile, which represent extremes of a 
spectrum of functional phenotypes (25, 26). M1 macrophages are 
activated by pro-inflammatory Th1 cytokines and LPS. Besides 
being antigen-presenting cells, the M1 subset shows an enhanced 
microbicidal capacity attributable to the production of reactive 
oxygen species (ROS) (such as hydrogen peroxide, superoxide, 
nitric oxide (NO), and peroxynitrite) and inflammatory cytokines 
(TNF, IL-1β, IL-12, and IL-23). On the other extreme, M2 mac-
rophages are activated by Th2 cytokines (IL-4 and IL-13) or by 
anti-inflammatory mediators (IL-10), enhancing the arginase 
activity and mannose receptor (CD206) expression, to promote 
wound healing and reduce Th1 response. However, the M2 subset 
development can also be detrimental to host tissue, leading to 
fibrosis when their matrix-enhancing activity is not regulated 
(27). Although embryonic and monocyte-derived macrophages 
likely are on a continuum spectrum that lies between (and outside 
of) the M1 and M2 classifications, the terminology nevertheless 
has been helpful in order to elucidate macrophage heterogene-
ity. When Ly6Chigh monocytes are recruited to atherosclerotic 
lesions, they mature to F4/80+ macrophages. In a persistent 
inflammatory environment, these Ly6Chigh monocyte-derived 
macrophages contribute to oxidative stress and are inflammatory 
FiGURe 2 | Human circulating monocyte subsets. Human blood monocytes can be separated into three subsets according to the CD16 and CD14 expression: 
classical monocytes (CD14++ CD16−), which represent the majority of circulating monocytes produce the anti-inflammatory IL-10 upon stimulation; intermediate 
monocytes (CD14++ CD16+); and non-classical monocytes (CD14+ CD16++), which secrete inflammatory cytokines such as IL-1β, IL-12, TNF, and antimicrobial 
molecules [nitric oxide (NO) and reactive oxygen species (ROS)].
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by producing IL-1β and TNF (9). In this respect, Ly6Chigh 
monocyte-derived cells are M1 macrophages. In the setting of 
inflammation resolution, M1 macrophages are replaced by M2 
repairing macrophages. Although it has been proposed that M1 
to M2 conversion occurs locally (28–30), M2 macrophages also 
could derive from non-classical and less inflammatory Ly6Clow 
monocytes (12). Otherwise, M2 macrophages may arise through 
direct differentiation of Ly6Chigh monocytes in a microenviron-
ment that favors wound healing. This option should be further 
explored because it is enticing for potential therapeutic reasons.
Cardiac resident macrophages coexpress M1 and M2 mark-
ers suggesting no specific polarization (31). However, within 
myocardium macrophages respond to systemic Th2 environ-
ment induced by helminth parasites infection, adopting an M2 
phenotype associated with enhanced fibrosis. In this model, 
the increased amount of cardiac macrophages relies on recruit-
ment of Ly6ChighCCR2+ monocytes instead of IL-4-induced 
expansion. In this sense, Jenkins et al. have shown that IL-4 and 
IL-13 through IL-4Rα not only activate macrophages but also 
cause proliferative expansion of resident macrophages (32, 33). 
Moreover, IL-33 also induces macrophages proliferation, but in 
an IL-4Rα-signaling-independent manner (34), suggesting that 
the number and activation state of cardiac macrophages largely 
depend on mediators locally produced.
ReLevANCe TO CARDiOvASCULAR 
PATHOLOGieS
Mononuclear phagocytes are becoming increasingly recog-
nized as key cells in the initiation and propagation of cardiac 
injury and remodeling. This growing body of evidence should 
prompt cardiovascular researchers to explore new therapeutic 
targets. Because of their functional and phenotypic versatility, 
manipulating specific macrophage subsets may spare key and 
vital cardiovascular functions, such as tissue repair and defense 
against pathogens, while preventing specific deleterious effects 
that contribute to adverse cardiac remodeling or atherosclerotic 
plaque formation.
infections
Chagas Cardiomyopathy
Chagas disease is caused by Trypanosoma cruzi infection and 
constitutes a major public health problem in Latin America due 
to its prevalence, morbidity, and mortality. The World Health 
Organization (WHO) classifies it as a neglected tropical disease, 
and has recently estimated that 6–7 million people worldwide are 
infected, and about 7,000 people annually die (35). The cardio-
myopathy represents the most frequent and serious complication 
of Chagas disease, affecting about 30–40% of infected individuals. 
In consequence, Chagas myocarditis is the most common form of 
infectious cardiomyopathy worldwide.
The clinical course of the disease is divided into acute and 
chronic phases. During the acute phase, which lasts 2–4 months, 
the infective trypomastigote form is in the bloodstream and 
invades target cells, where it replicates as amastigote form. This 
stage is followed by a life-long chronic phase, in which parasites 
are cleared from the circulation but persist for years within the 
myocardium among other target tissues. Nowadays, it is widely 
accepted that the persistence of parasites in target tissues coupled 
with an unbalanced immune response is a necessary and suf-
ficient condition for the development of the cardiomyopathy 
(36–39).
In response to the infection, macrophages are one of the main 
infiltrating leukocytes arriving early to the myocardium (40) and 
they remain as an important immune cell population in heart 
explants from patients with severe advanced chronic Chagas 
disease (41). Interestingly, selective depletion of macrophages 
causes a significant increment in the number of amastigote nests 
within cardiomyocytes, suggesting a crucial role for macrophages 
in the resistance to this infection (42). Even though several anti-
parasitic roles of these cells in Chagas disease has been further 
documented, the functional characterization of resident and 
FiGURe 3 | Role of macrophages in the immune response against Trypanosoma cruzi infection. Macrophages are the main infiltrating cells arriving to the 
myocardium early after T. cruzi infection. Different mediators can regulate the magnitude and quality of the cardiac immune response by modulating macrophages 
activation. (A) ATP is released by infected/injured cells and hydrolyzed by two ectoenzymes, CD39 and CD73, to the immunoregulatory metabolite ADO. 
Pharmacological inhibition of CD73 activity with APCP enhances M1 over M2 macrophage phenotype and increases the local production of TNF, IL-1β, IL-6, and 
NO and diminished IL-10 levels. (B) IL-6 is a pleiotropic cytokine that contributes to the establishment of cardiac M2 macrophage profile during T. cruzi infection by 
inducing an anti-inflammatory microenvironment and augmented CD39 expression. Deficiency of IL-6 (IL6KO mice) dysregulates inflammasome activation with a 
consequent increases in IL1-β-induced NO production. The excessive oxidative stress and exacerbated pro-inflammatory immune response cause the lethal effect 
observed in infected IL6KO mice.
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infiltrating macrophages in infected myocardium has not been 
widely studied until very recently. In this sense, we have described 
the kinetics of macrophage populations during the acute and 
chronic phase of T. cruzi infection in BALB/c and C57BL/6 car-
diac tissue (43, 44). In both mouse strains, macrophages with M1 
phenotype (CD45+ F4/80+ CD11b+ CD86+ CD206−) predominate 
only at short times postinfection [4 days postinfection (dpi)], but 
then macrophages are rapidly polarized toward M2 phenotype 
(CD45+ F4/80+ CD11b+ CD86− CD206+), which remains sus-
tained during the acute and chronic phase (90 dpi). The sudden 
shift in cardiac M1/M2 ratio correlates with the changes in local 
cytokine milieu. These works evidence that alternatively activated 
macrophages are the main cardiac cell subset throughout the 
infection. Alternative macrophages provide protection against 
overwhelming cardiac inflammation, but they also interfere with 
the activation of M1 macrophages and its microbicidal function, 
promoting parasite persistence. The sustained M2 profile is pro-
moted, at least in part, by the action of IL-6 (44).
In order to stablish the possible mechanisms by which cardiac 
M1 macrophages shift toward M2 profile quickly after infection, 
we focused on purinergic signaling. The ecto-5′-nucleotidase 
(CD73) enzyme is part of the purinergic system and together 
with ectonucleoside triphosphate diphosphohydrolase-1 (CD39) 
metabolize, in a step-wise manner, the extracellular ATP into 
adenosine (ADO). ADO has a regulating role on macrophage 
functions associated with M1 profile, such as suppression of 
chemokines and pro-inflammatory cytokines production, 
impairment of inducible nitric oxide synthase (iNOS) activity 
and induction of anti-inflammatory IL-10 production (45). 
CD73 is the rate-limiting enzyme in the ADO generation and it 
is expressed by immune and parenchymal cells (46). We showed 
that pharmacological inhibition of CD73 enzymatic activity with 
ADO 5′α,β-methylene-diphosphate (APCP) during the early 
acute phase enhances the number of M1 cardiac macrophages 
over the M2 subset and increases cardiac levels of NO, IL-6, TNF, 
and IL-1β in infected BALB/c mice (Figure 3A). These APCP-
induced changes result in a concomitant reduction of cardiac 
parasite load during the acute phase and, as a direct consequence, 
improve the outcome of chronic cardiomyopathy (43). The study 
demonstrates that the polarization of cardiac macrophages is 
strongly influenced by the products of extracellular ATP metabo-
lism and that the manipulation of this pathway could provide new 
approaches to reduce Chagas heart pathology.
In response to different cardiac injuries, soluble mediators 
are key players since they drive the immune response and the 
reestablishment of homeostasis. In this sense, IL-6 cytokine is 
suddenly and continuously produced by cardiomyocytes and 
neighboring cells after different pathological stimuli, suggesting 
that this cytokine is clue for the heart’s intrinsic stress response 
system. We and others have reported that IL-6-deficient (IL6KO) 
mice succumb to T. cruzi infection very early during the acute 
phase (44, 47, 48). By analyzing immune mechanism that could 
explain the lethal effect observed in the absence of this cytokine, 
we discovered that IL-6 negatively regulates inflammasome 
activation and, consequently, IL-1β-induced NO production, and 
that excessive oxidative stress accounts for the increased mortal-
ity of infected IL6KO mice (44). We also found that IL-6 promotes 
the establishment of M2 cardiac macrophage profile during infec-
tion and induces in vivo and in vitro expression of the enzyme 
CD39 on macrophages, suggesting that IL-6 could promote a 
shift from an ATP driven pro-inflammatory environment to an 
anti-inflammatory milieu induced by ADO (44) (Figure  3B). 
Considering that IL-6 is a therapeutic target in individuals with 
different inflammatory diseases (49), our results provide the basis 
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for understanding why blocking IL-6 in certain clinical situations 
does not represent an effective treatment; instead triggering pro-
inflammatory adverse events.
In agreement with the results obtained with the mouse experi-
mental model, the culture of in vitro-infected peripheral blood 
mononuclear cells obtained from control human donors with IL-6 
blunted T. cruzi-induced nitration of cytotoxic T-cell subpopula-
tion and increased their survival. The nitration of surface proteins 
on T cells is a consequence of NO and superoxide anion reaction 
which generates peroxynitrite. Furthermore, the blockade of IL-6 
in these cultures with an IL-6 neutralizing antibody increased 
the frequency of T. cruzi-induced nitration of CD8+ T  cells as 
a consequence of elevated NO production. In line with these 
results, leukocytes from chronic Chagas patients show increased 
NO production concomitant with significant tyrosine nitration 
mainly in CD8+ T  cells compared with seronegative patients. 
Superficial tyrosine nitration on cytotoxic cells is concomitant 
with impaired effector functions and lower capacity for activa-
tion but also it is associated with a significant fall in the number 
of circulating CD8+ T cells (50). Altogether, the results suggest 
that CD8+ T cell functionality decreases in the setting of human 
Chagas disease, but this under-responsiveness could be reverted 
by the pleiotropic actions of IL-6, which functions as a survival 
factor for this population and improves its effector functions. 
Strikingly, the parasite has evolved strategies to counteract IL-6-
dependent signaling through the specific cleavage of its receptor, 
the gp130 chain (51).
In contrast to the antioxidant properties of IL-6, IFN-γ 
enhances iNOS expression in infected macrophages resulting in 
the killing of intracellular parasites. Strikingly, IL-17A-stimulated 
macrophages control replication in a comparable level to IFN-γ 
treatment (52). The IL-17 stimulation alters the uptake pathway 
of trypomastigotes promoting phagocytosis over active invasion 
of macrophages. Phagocytosis of trypomastigotes enhances the 
number of internalized parasite and prolongs its residency in the 
endosomal/lisosomal compartment. A recent report demonstrates 
that IL-17-mediated direct protection of infected macrophages 
involves the NADPH oxidase activation and ROS production 
(53). In concordance, mice deficient in IL-23 (IL23p19KO), a 
potent inducer of IL-17A production, show enhanced parasitemia 
and a greater susceptibility to acute T. cruzi infection compared 
with infected WT mice. Moreover, IL-17AKO mice seemed to 
be even more susceptible to T. cruzi infection than IL23p19KO 
mice. The fact that the treatment of macrophages with IL-17A 
plus IFN-γ is more efficient to eliminate the parasite compared 
with single-cytokine stimulation, might explain the higher mor-
tality ratio in IL23p19KO and IL-17AKO mice even though the 
Th1 immune response, measured by IFN-γ production and the 
iNOS expression, is not impaired during the infection in both KO 
mice (52). Finally, correlation analysis in Chagas disease patients 
demonstrates that high IL-17 serum levels are associated with 
better cardiac function (54–56).
After reaching the cytosol in macrophages, T. cruzi is 
recognized by innate receptor NLRP3, a member of nod-like 
receptor family (57). Infected mice deficient in IL-1β receptor, 
ASC, or caspase-1 are defective in NO production and exhibit an 
enhanced cardiac parasitism and mortality (58). Furthermore, 
the weak IL-1β production in NLRP3KO macrophages is 
compensated by an enhanced ROS production that mediates 
an effective parasite killing, indicating that NLRP3 modulates 
NADPH oxidase/ROS levels (59). Moreover, these low levels of 
IL-1β and the partial survival of infected NLRP3KO mice suggest 
that another Nod-like receptor might be activating inflamma-
some during infection.
Following cardiac injury, immune cell infiltration and fibrob-
lasts migration trigger tissue remodeling, that is largely dependent 
on matrix metalloproteinases (MMPs) activity. Immunohisto-
chemistry analysis revealed that vascular wall and infiltrating 
leukocytes are the cellular source of MMP-2 and MMP-9, which 
are increased in cardiac tissue during the acute phase of T. cruzi 
infection. As expected, treatment with MMP inhibitors reduces 
myocarditis in infected mice (60). In Chagas disease patients, 
T  cells, neutrophils and monocytes are source of MMP-2 and 
MMP-9. In vitro stimulation with T. cruzi-derived antigens 
induces higher MMP-2 and MMP-9 expression in monocyte 
from patients with cardiac clinical forms of Chagas disease com-
pared with those from non-infected patients (61). Recent reports 
showed a significant positive correlation between the levels 
of MMP-9, IL-1β and TNF, but a negative correlation between 
MMP-2 levels and these inflammatory cytokines and a positive 
correlation with IL-10 expression in serum from chronic Chagas 
disease patients (61, 62). These results suggest that MMP-9 
may be related to inflammation and cardiomyopathy develop-
ment; meanwhile, MMP-2 would be associated with regulation 
of chronic inflammatory process. Other study indicated that 
MMP-2 and MMP-9 levels peaks in plasma from patients clini-
cally asymptomatic with an abnormal ECG (an early indicator 
of cardiac disease) and progressively augmented in patients with 
advancing Chagas cardiomyopathy. Although MMPs are strongly 
associated with several inflammatory diseases, the data suggested 
that MMP-2 and MMP-9 plasmatic levels could be used as early 
biomarkers of cardiac disease (63).
It is widely accepted that T. cruzi modulate apoptosis of different 
target cells in order to evade the immune response. In this sense, 
Freire-de-Lima and coworkers demonstrated that phagocytic 
removal of apoptotic T  lymphocytes by infected-macrophages 
exacerbate parasite replication by driving its differentiation 
toward an M2-like phenotype concomitant with TGF-β, IL-10, 
and PGE2 production (64, 65). TGF-β promotes in macrophages 
the L-arginine metabolism by arginase to synthesize polyamines 
which functions as a growth factor for parasites (66). Another 
work found that blocking apoptosis of CD8+ T cells in cocultures, 
infected macrophages increase NO levels and M1 features leading 
to restrict intracellular parasite growth (67). In addition, while 
coculture of apoptotic neutrophils induce an M2-like phenotype 
in infected macrophages, live neutrophils via elastase induce 
M1 macrophages with NO and TNF production that allow to 
control T. cruzi replication (68). Further studies in human cells 
are needed to validate these findings.
Similar to others cardiac pathologies, cardiomyocyte apopto-
sis seems to be determinant of Chagas disease progression. In this 
sense, it was found that infection induces apoptosis of cardio-
myocytes (69, 70). In contrast, several reports demonstrated that 
T. cruzi induces anti-apoptotic effect on cardiac cell (51, 71–75). 
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Indeed, it is plausible to think that cardiac cell exposure to pro-
inflammatory milieu may precondition the heart tissue to protect 
cardiomyocytes from a massive apoptosis (76). This hypothesis 
is clinically supported by experiments performed by Metzger 
et al. The authors described that apoptotic cells are increased in 
the myocardium from Chagas disease patients with severe heart 
failure. However, the apoptotic cells are not cardiomyocytes, 
and the majority of TUNEL+ cells are also CD68+ (human 
macrophage marker) (77), similar results also being observed by 
other researchers (78). Related to this, an intense Bcl-2 expres-
sion is induced in cardiomyocytes during the acute phase of the 
experimental infection, likely establishing a higher threshold to 
apoptosis in this cell type (73).
Although enthusiastic researchers have suggested the thera-
peutic use of apoptosis inhibitors as an attractive choice for adju-
vant therapy during the chronic phase (79), the effects of apoptosis 
modulation on the outcome of chronic cardiomyopathy requires 
further studies.
Viral Myocarditis
The cardiotropic viruses that cause myocarditis in humans include 
enteroviruses, adenoviruses, influenza viruses, cytomegaloviruses, 
parvoviruses, and herpes viruses. Although most of these viruses 
commonly cause only mild upper respiratory or gastrointestinal 
complications in most individuals, a few infected people develop 
cardiac clinical symptoms (80). The enteroviral coxsackievirus B 
group type 3 (CVB3), adenoviruses parvovirus B19, and human 
herpes virus 6 are frequently observed in myocarditis biopsies. 
The most common viral myocarditis is caused by CVB3 infection. 
It affects about 5–20% of world population, and yet lacks efficient 
treatments. Although acute viral myocarditis is self-limiting in 
most individuals, in others develop chronic myocarditis, progres-
sive cardiac fibrosis, dilated cardiomyopathy, heart failure, and 
even death (81–83). Strong clinical and experimental evidence 
has demonstrated that two main mechanisms are involved in 
pathogenesis of CVB3-induced myocarditis, first a direct viral 
injury to cardiac cells during the acute stage of infection and sec-
ond, the excessive pro-inflammatory immune response against 
CVB3 which can subsequently evolve to a chronic autoimmune 
cardiac pathology in some susceptible patients (80).
Monocytes/macrophages represent one of the major infiltrat-
ing inflammatory cells in CVB3-induced myocarditis. It was 
reported that cardiac CCL2 levels are significantly enhanced at 
1  dpi and peak at 4  dpi and hence closely involved in CVB3-
induced myocarditis initiation, by attracting monocytes. CCL2 
incidence in viral myocarditis was even more evident after 
blocking CCL2 activity in vivo, since those infected mice exhibit 
reduced myocardial cell infiltration, decreased serum CK-MB 
levels and increased host survival (82).
Other study showed that in  vivo CVB3 infection also trig-
gers the production of galectin-3 (a β-galactoside binding 
lectin) in cardiac macrophages during acute and chronic phases. 
Abrogation of galectin-3 expression or its pharmacological inhi-
bition does not affect viral titers but reduce acute myocarditis and 
chronic fibrosis, suggesting a critical role of galectin 3-producing 
macrophages in the induction of fibrosis subsequent to CVB3 
infection.
Studies in experimental murine infection with CVB3 have 
been widely employed as a model of human enteroviral infection 
and they have significantly contributed to the understanding of 
the immunological mechanisms underlying acute and chronic 
viral inflammatory heart disease. Strikingly, male, but not 
female, mice infected with CVB3 present a severe myocarditis 
with a pathological process resembling human disease. Although 
similar viral infection titers have been detected in patients of both 
genders, the estimated incidence of myocarditis in men is twofold 
increase or more than in women (84, 85).
Experimental approaches assessing the differential suscep-
tibility against CVB3 infection between male and female mice 
have greatly contributed to the knowledge of the etiopathological 
mechanisms of this viral myocarditis. During the early acute 
infection, cardiac tissue from male and female mice presents high 
levels of IFN-γ and IL-4, respectively. Consistently, male cardiac 
macrophages express M1 markers; meanwhile, female cardiac 
macrophages polarize toward M2 phenotype (86, 87). Employing 
adoptive transfer experiments of in  vitro IFN-γ-induced M1 
macrophages, the authors demonstrated this pro-inflammatory 
subset is responsible for myocardial inflammation and damage 
after CVB3 infection (86).
It is important to highlight that IL-10 has a protective role dur-
ing virus-induced cardiac fibrotic process by inhibiting fibroblast 
collagen synthesis (85, 88). As counterpoint, male infected mice 
exhibit a reduced frequency of cardiac monocytic-myeloid-
derived suppressor cell (MDSC) subset and regulatory T  cells, 
which negatively correlates with the severity of cardiac fibrosis 
induced by CVB3 infection. Although it was reported that myo-
cardial infiltrating immune cells have a different cell composition 
in both mouse genders, how this difference affects macrophage 
functions and the development of CVB3-induced myocarditis 
needs further studies. In this sense, infiltrating NK  cells could 
have a role in the physiopathology of the disease. Kinetic studies 
of myocardial infiltrate revealed that NK  cells arrive together 
with macrophages and the synergistic action of sex hormones 
and CVB3 infection contribute to NK cells differential cytokine 
production (87).
On the other hand, it was reported that CVB3 can efficiently 
induce endoplasmic reticulum (ER) stress in infected cardiomyo-
cytes and, in turn, stressed myocardial cells transfer the ER stress 
to macrophages via some unknown soluble molecules and facili-
tate the pro-inflammatory phenotype. In concordance, an in vivo 
pharmacological treatment with ER stress inhibitor induces a 
substantial reduction of pro-inflammatory cytokines in mac-
rophages, diminishes CK-MB serum levels, relieves myocardial 
inflammation and improves cardiac functions. Moreover, adop-
tive transfer experiments of ER stress-inhibited macrophages into 
infected mice also alleviate viral-myocarditis together with an 
increase in mice survival, confirming the pathological role of ER 
stressed macrophages in CVB3-induced myocarditis (89). Other 
work showed that CVB3 infection in cardiac cells induces ROS 
production and alters potassium efflux, triggering NLRP3 inflam-
masome activation in infected cardiomyocytes (90). Therefore, 
all these studies indicate that the cardiac environment that shape 
macrophages polarization has a key role in the outcome of CVB3-
induced heart disease.
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Bacterial Infections
Mononuclear phagocytic cells are essential in cardiac immunity 
to several myocarditis-related to bacterial infections. Lyme 
disease is a long-term infection caused by Borrelia burgdorferi 
spirochetes. Its most severe complications are myocarditis and 
inflammatory arthritis of the lower bearing joints. An important 
difference between arthritis and myocarditis is the distribution 
of phagocytes within the lesions; while polymorphonuclear 
leukocytes are more prevalent in the joint, macrophages are the 
predominant infiltrating cells in infected hearts (91). The severity 
of Lyme myocarditis is controlled by CD11c integrin, because 
CD11cKO mice caused increased cardiac MCP-1 production and 
consequently, increased macrophage infiltration. The loss of this 
integrin generates an impaired macrophage immune response 
leading to an aggravated Lyme disease (92). Similarly, in absence 
of CCR2, the receptor that induces monocyte recruitment to the 
site of infection, resistant CCR2KO mice had augmented bacterial 
heart burden compared with WT counterpart (C57BL/6) suggest-
ing a reduced clearance of the bacteria. In contrast, deficiency of 
CCR2 in sensitive mice strain CCR2KO (C3H) produced severe 
inflammation with increased presence of polymorphonuclear 
cells but decreased B. burgdorferi burden in comparison with 
WT (C3H/HeJ) mice. The less efficient spirochete clearance from 
hearts of WT C3H mice compared with CCR2KO C3H mice 
suggests an impaired recruitment or function of macrophages 
in C3H mice, which may contribute to the susceptibility of this 
animal strain to B. burgdorferi infection (93). Nevertheless, there 
were no differences in cardiac macrophage polarization of C3H 
sensitive strain, with similar number of M1 and M2 subtype 
macrophages at the peak of inflammation (94).
Regarding cytokine production, there are several reports 
showing that IFN-γ is a key cytokine that modulates the immune 
response to B. burgdorferi, particularly the macrophage activation 
and functions. Sabino and coworkers proposed that IFN-γ influ-
ence the composition of cardiac leukocyte infiltrates. They found 
that B. burgdorferi and IFN-γ synergistically enhance the secre-
tion of mononuclear cell chemoattractants such as CXCL9 and 
CXCL10, decrease those for neutrophils (CXCL1 and CXCL2), 
and, in consequence, this modifies the nature of the cellular infil-
tration (95). Additionally, the production of IFN-γ by iNKT cells 
enhance the bacterial recognition and activation of macrophages 
as evidenced by augmented TNF and IL-6 production, leading 
to an increased phagocytic activity (91). Importantly, IFN-γ is 
produced in lesions of Lyme patient myocarditis and its levels 
positively correlate with the severity of the pathology.
Considering innate receptors, it was reported that mice defi-
cient in the intracellular adapter molecule myeloid differentiation 
antigen 88 (MyD88KO), which is required for several TLR-induced 
inflammatory responses had 250-fold higher pathogen burden 
than WT mice. In agreement, in vitro experiment confirmed that 
MyD88KO macrophages phagocytize spirochetes but degrade 
them more slowly than WT macrophages (96). In accordance, 
Hawley et  al. demonstrated that CR3KO-mediated spirochete 
internalization requires the participation of CD14 molecule as an 
accessory receptor and showed that CR3/CD14-mediated phago-
cytosis generates a pro-inflammatory macrophage phenotype in 
response to bacterial invasion (97). On the other hand, several 
reports demonstrate key roles for the intracellular innate receptor 
Nod2. In B. burgdorferi infection context, Nod2-deficient mice 
resulted in increased myocarditis compared with control mice. 
Although Nod2 induces inflammatory milieu in in vitro models 
of B. burgdorferi infection, BMDM upon a prolonged stimula-
tion of Nod2 no longer respond in the same manner. Indeed, 
prolonged exposure to the Nod2 ligand results in suppression 
of pro-inflammatory responses. The authors theorize that the 
dual role of Nod2 signaling in the inflammatory response may 
be associated with the chronicity of the infection (98). In the 
same way, Zlotnikov et al. revealed that a high fat diet-induced 
obesity (DIO) in a murine model of Lyme disease was associ-
ated with systemic suppression of innate immune response. The 
hearts of DIO-infected mice presented significantly elevated 
inflammation and increased bacterial burden due to an impaired 
bacterial uptake and pro-inflammatory cytokine production by 
macrophages and this effect became more pronounced as infec-
tion progressed (99). All these data together substantiate the 
importance of macrophages in the immune response against this 
pathogen, but also the dual role that they can play in order to 
control the infection or perpetuate the inflammation state.
Other bacterial infection in which macrophages play a 
key role on disease outcome is poststreptococcal myocarditis. 
Streptococcus pneumoniae is capable of invading the heart soon 
after the development of bacteremia. The pneumococcus is the 
responsible of the community-acquired pneumonia and some-
times it may worsen by producing the invasive pneumococcal 
disease that injures the heart. Macrophages have been postulated 
as inducers of heart-reactive T cells due to their capacity to trans-
fer the inflammatory lesions into normal recipient mice when 
they are pulsed with group A streptococcus extract (SAE) result-
ing in an increased serum CK levels, an enzyme that is released 
in the bloodstream after inflammatory cardiac muscle injury. 
SAE pulsed macrophages may present to T  cells an antigenic 
determinant characteristic to rheumatogenic streptococci that 
cross-reacts with a normal component of the heart tissue (100). 
In accordance, group A streptococcal M proteins had the ability 
to stimulate human PBMC to proliferate and induce cytotoxic 
T  cells against cultured human heart cells (101). The results 
suggest a critical role for monocytes/macrophages as antigen-
presenting cells in the outcome of heart damage after infection.
More recent studies have proposed that S. pneumoniae forms 
discrete pneumococcus-filled micro lesions in the myocardium 
during invasive pneumococcal disease (102) generating direct 
tissue damage. The pneumococci within cardiac micro lesions 
produce pneumolysin, a cholesterol-dependent pore-forming 
toxin, which kills cardiomyocytes and macrophages due to 
pneumolysin-induced necroptosis. This precludes the generation 
of an effective immune response and perpetuates cardiac damage 
(103). These reports bring to light that macrophages are crucial 
for innate immune response to bacterial infections and that the 
alteration of their functions can alter the outcome of the disease.
Sterile inflammation
Although inflammation is the process in which components of the 
innate immune system respond to an injury or infection, inflam-
matory response can also be triggered in absence of infection by a 
FiGURe 4 | Role of macrophages in the pathogenesis of atherosclerosis. Disturbance of normal vascular physiology is characterized by endothelial activation which 
stimulates the expression of endothelial adhesion molecules (VCAM-1, ICAM-1) to favor the passage of inflammatory monocytes to the subendothelium. Modified 
LDL and other DAMPS are recognized by pattern-recognition receptors such as CD36 (scavenger receptor-B) in infiltrating macrophages. Thus, these innate cells 
are transformed into lipid-laden foam cells in the vasculature intima. The activation of NF-κB in response to ox-LDL induce the secretion of inflammatory cytokines 
(IL-1β, TNF), NO, MCP-1, and macrophage-derived matrix metalloproteinases (MMPs) that degrade the extracellular matrix generating a maladaptative inflammatory 
response and contribute to plaque formation.
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process known as sterile inflammation. This type of inflammation 
is implicated in the development of a variety of clinical conditions 
such as atherosclerosis, cardiac injury, neurodegenerative and 
metabolic disorders. Unlike microbial-induced inflammation, 
sterile inflammation is activated by endogenous danger- 
associated molecular patterns (DAMPs) released as a consequence 
of cellular injury and/or inflammation, such as oxidized low-
density lipoprotein (oxLDL), oxidized phospholipids (oxPLs), 
amyloid β or uric-acid crystals (104, 105). This sterile inflamma-
tory response induces recruitment of neutrophils and monocytes 
leading to production of pro-inflammatory cytokines and 
chemokines, mainly IL-18 and IL-1β in a caspase-1-dependent 
manner. As mentioned above, monocytes subsets (classical, inter-
mediate, and non-classical) extensively participate in the response 
to infectious disease; however, their role in sterile inflammation 
in cardiac ischemia-reperfusion injury and atherosclerosis is still 
not well understood. Myocardial ischemia-reperfusion injury is a 
condition that involved cardiomyocytes death affecting contract-
ibility and loss of heart function as a result of a vascular occlusion 
and loss of tissue irrigation. While different pathways contributed 
to limit the damage, the inflammatory response in the ischemic 
heart can be detrimental (106).
The knowledge gained on the origin of resident cardiac 
macrophages has greatly improved the therapeutic potential of 
macrophage manipulation in the context of sterile inflammation. 
Considering that adult mammalian heart contains two mac-
rophage pools which include: Ly6Clow MHC-IIlow and MHC-IIhigh 
(CCR2−) representing embryonically established macrophages 
and the second pool and much less abundant derived from blood 
Ly6Chigh CCR2+ monocytes. Altered homeostasis induced by 
transient depletion (chemically) of monocytes and macrophages 
population in heart shown proliferation of CCR2− resident 
macrophages and recruitment of Ly6Chigh CCR2+ monocytes 
from blood to contribute to tissue macrophages repopulation 
(107). Thus, after myocardial injury and knowing that NLRP3 
inflammasome activation impair tissue regeneration, blockage 
of CCR2 abolishes ischemic damage. This concept suggests that 
blockage of CCR2+ monocytes influx or recruitment during 
cardiac ischemia-reperfusion will be protective, while a strategy 
of depletion of resident macrophages (CCR2−) abolished that 
protection. In the same way, Marchetti et  al. applied a phar-
macological inhibitory strategy for NLRP3 inflammasome in 
a mouse model of myocardial injury. They found that in acute 
myocardial infarction (MI) with reperfusion and in a model of 
non-ischemic injury induced with doxorubicin, the inhibition of 
NLRP3 inflammasome cause a significantly reduction of infarct 
size and preserved systolic function (108).
The understanding of circulating monocytes and cardiac 
macrophage biology under physiology and disease condition 
may help discover new mechanisms to target specific subset 
population of macrophage that impact in cardiac cytoprotective 
pathways.
Atherosclerosis
Atherosclerosis is the result of lipid accumulation and chronic 
inflammation in the arterial wall where macrophage plays a 
central role in the development and progression of plaque 
formation (Figure  4). Thus, transmigration of monocytes into 
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the subendothelial space, lipid uptake (oxLDL) and foam cell 
differentiation are key step in atherogenesis. The maintenance of 
a healthy endothelium regulates the precise balance in vascular 
homeostasis between vasoconstriction and vasodilation, trom-
bogenesis and fibrinolysis, cellular migration and proliferation 
(109). Disturbance of normal vascular physiology is character-
ized by endothelial activation, which may be caused by infection 
or by cardiovascular risk factor such as hyperlipidemia (patho-
physiologic). Thus, pro-inflammatory mediators (IL-1β, TNF, 
and MCP-1) induce a deleterious effect on NO bioavailability 
increasing ROS which stimulate the expression of endothelial 
adhesion molecules (VCAM-1, ICAM-1) to favor the passage 
of monocytes to the subendothelium and promoting their dif-
ferentiation into macrophages (110).
In atherosclerosis, circulating low-density lipoprotein (LDL) 
molecules undergoes modifications mainly oxidation, acetylation 
and glycation that alter the normal metabolism of lipoprotein to 
promote cytotoxic damage on endothelial cells and macrophages. 
There is a broad spectrum of mediators that induce LDL oxida-
tion from enzymatic (lipoxygenase and cyclooxygenase) to 
non-enzymatic reactions (free radicals and oxidants). Some of 
these reactions have differential selectivity for LDL components 
as occur with ROS that oxidize predominantly the lipid portion of 
LDL or the neutrophil myeloperoxidase that oxidize the protein 
portion (Apo B) of LDL by action of hypochlorous acid byprod-
ucts (111, 112).
In this inflammatory milieu, other biomolecules, in addition 
to LDL, such as lipids and proteins are target of oxidation and 
nitration reactions generating new species that may affect the fate 
of the plaque development and limit or exacerbate the inflamma-
tory state. Thus, nitro-fatty acids (NO2-FAs) are the product of the 
reaction of unsaturated fatty acids and nitrogen-derived species 
(NO and nitrites) (113). Administration of NO2-FA in a mice 
model of atherosclerosis (ApoEKO) exhibited anti-inflammatory 
and protective actions, decelerating the development of the ath-
eroma plaque, affecting oxLDL uptake and foam cell formation 
in macrophages (114).
Modified LDLs are recognized and internalized in macroph-
ages by pattern-recognition receptor (PRR) which includes scave-
nger receptor (SR) and toll-like receptor (TLR). SRs bind diverse 
ligands and contribute to the clearance of foreign or modified 
particles. Regarding to macrophage cholesterol metabolism, 
CD36 (SR-B) and SR-A1 mediate internalization of oxLDL 
and transform these cells into cholesterol-laden foam cells in 
the vasculature intima. Exploration in experimental models 
evidenced that CD36-deficient macrophages exhibited a reduced 
uptake of oxLDL; further study in ApoE/CD36 double mutant 
mice described the reduction of the size of atherosclerotic plaque 
(115, 116). These results emphasized the role of CD36 as a 
pro-atherogenic receptor in the vasculature and cardiovascular 
disease. However, discrepancy on CD36 implication as pro- or 
anti-atherogenic has been raised by other studies in which 
described advanced atherogenesis in LDLR/CD36 double mutant 
mice or less macrophage accumulation but increased aortic lesions 
in ApoE/CD36 double KO (117). The inconsistency of this result 
may be in part explained by the different experimental model and 
animal background employed. Besides the discrepancy on CD36 
function in atheroma plaque formation the binding of oxLDL 
stimulates pro-inflammatory signaling pathways (NF-κB) in 
macrophage contributing to maintain the chronic inflammatory 
state generated during the onset of atherosclerosis disease.
In atherosclerosis, the recognition of the subsets of recruited 
monocytes that differentiate into macrophages in the atheroma 
plaque may be relevant to design new strategies to treat patho-
logical inflammatory process. During the development of ath-
eroma plaque, the recruitment of monocytes are drawn from the 
Ly6Chigh circulating subset (precursor of M1 macrophages) but 
after treatment and control of hyperlipidemia a rapid reduction of 
plaque inflammation and regression was exhibited, characterized 
by decrease number of macrophages and the relative increase in 
markers of M2 macrophages state. Rahman et  al. described in 
a model of aortic arch transplantation that plaque regression is 
characterized by recruitment of Ly6Chigh circulating monocytes 
and the posterior polarization to M2 phenotype (118). This result 
is contrary to the prevailing paradigm about M2 macrophages 
recruitment in plaque regression and the authors promote the 
strategy of M2 macrophage accumulation in atherosclerotic 
lesions to stimulate plaque regression. Consistent results were 
obtained in mice treated with IL-13 and IL-4 (promote M2 polari-
zation) which describe protective effects in plaque progression in 
mice (119).
Summing up, the data obtained clearly illustrate the clue role 
that mononuclear phagocytic cells play in the development of 
the atherosclerotic pathology, further molecular mechanisms 
involved in plaque formation are described in the next chapter.
SiGNALiNG PATHwAYS AND MOLeCULeS 
MODULATiNG CARDiOvASCULAR 
iMMUNe ReSPONSe
Cytokines and Chemokines
Macrophages are major contributors to the inflammatory response 
in the setting of cardiovascular diseases. They secrete diverse 
pro-inflammatory mediators (including cytokines, chemokines, 
ROS and nitrogen species, among others), and MMPs and they 
eventually die by necrosis or apoptosis. Dying macrophages 
release their lipid contents, which lead to the development of a 
pro-thrombotic necrotic core. The necrotic core is, in turn, a clue 
component of unstable plaques and contributes to their rupture 
and the consequent intravascular blood clot that causes MI and 
stroke. The main effect of cytokines/chemokines released by 
macrophages is the recruitment of different innate and adaptive 
immune cell populations into the atherosclerotic lesions (120, 121), 
thereby amplifying the inflammatory environment. For example, 
different inflammatory mediators such as IL-1, TNF and IFN-γ 
increase the expression of MCP-1 in macrophages (120, 122). 
Also, under inflammatory conditions macrophages produce dif-
ferent enzymes such as MMPs, cathepsins and serine proteases 
that degrade the extracellular matrix of the atherosclerotic plaque 
contributing to the pathogenesis of atherosclerosis (123). In this 
sense, IL-1 and TNF increase the expression of numerous MMPs, 
such as MMP-9, and their activity contribute to unstable plaque 
morphology (123).
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While initial reports indicated that IFN-γ prevented macro-
phage foam cell formation (124), subsequent studies demon-
strate that this cytokine promotes foam cell formation through 
diverse mechanisms: enhancing the uptake of oxLDL/AcLDL 
through SRs (122, 125), diminishing efflux of cholesterol 
via inhibition of ABCA-1 transporter and ApoE expression 
(126, 127) and increasing ACAT-1 levels (126) in macrophage-
derived foam cells. For example, it was recently reported that the 
axis IFN-γ/STAT1 mediates the uptake of acLDL/oxLDL by human 
macrophages in an extracellular signal-regulated kinase (ERK)-
dependent signaling (125). The activity of IFN-γ as a pro-foam 
cell mediator has been supported by several in vivo studies (128).
Since IFN-γ was identified as a pro-foam cell cytokine, dif-
ferent authors evaluated the effect of other pro-inflammatory 
cytokines. Studies using a murine macrophage cell line have 
shown that TNF inhibits the expression of SRs and the uptake 
of oxLDL (129). Regarding additional mechanisms, more recent 
evidence has suggested that TNF promotes foam cell formation 
in vitro by reducing the mRNA expression of ABCA-1/ABCG-1 
(130), and intracellular lipid catabolism (131), and by enhancing 
the expression of ACAT-1 and the accumulation of cholesteryl 
ester (132). However, the role for TNF remains controversial since 
other studies have shown that TNF enhances ABCA-1 expression 
and the efflux of cholesterol in peritoneal macrophages stimu-
lated with ApoA–I (133, 134) and since evidences from studies 
performed in murine models are also contentious (128).
Regarding anti-inflammatory cytokines, it has been demon-
strated that TGF-β decreases CD36/SR-A expression and the 
uptake of oxLDL in human macrophages (135, 136). Additional 
data emphasized this anti-foam cell effect by showing that 
TGF-β downregulates CD36/SR-BI mRNA levels in peritoneal 
macrophages (137) and increases ApoA–I and HDL-stimulated 
cholesterol efflux and ABCA-1 gene transcription in foam cells 
(138). Argmann et al. (139) demonstrated that TGF-β1 decreases 
LPL expression/activity and cholesteryl ester accumulation with a 
coincident increase in the expression of ABCG-1 in murine mac-
rophages. Recently, it was reported that TGF-β diminishes LPL 
gene transcription (140) and increases the expression of ApoE 
(141). Moreover, other group has shown that CD4+ CD25+ regu-
latory T  cells use TGF-β1 to inhibit the uptake of oxLDL and 
the expression of CD36/SR-A mRNA (142). These mechanisms 
evidence an anti-foam cell role for TGF-β1, although it is impor-
tant to stress that TGF-β may promote development either of 
anti-atherosclerotic regulatory T cells or of T-helper 17 (Th17) 
cells, depending on factors in the local milieu. Therefore, TGF-β 
signaling in T cells could promote stabilization of atherosclerotic 
plaques through an IL-17-dependent pathway.
The effect of IL-10 on plaque formation has also been reported. 
This anti-inflammatory mediator downregulates the CD36 SR 
expression (143) and, in consequence, decreases the accumula-
tion of cholesterol in human macrophages (144). In addition, two 
independent groups have reported anti-foam cell activity of IL-10. 
Indeed, they found that IL-10 enhances the uptake and efflux of 
cholesterol by human macrophages in  vitro and reduces foam 
cell formation and atherosclerotic plaque progression in  vivo 
(145, 146). Altogether, the results suggest that IL-10 counteract 
atherogenesis.
Besides M1 and M2 macrophage profiles, additional phe-
notypes have been described within atherosclerotic lesion and 
they have become a topic of increasing relevance. In areas of 
hemorrhage, macrophages respond adaptively to heme acquiring 
an activation status that was designated hemorrhage-associated 
macrophages (Mhem). In vitro human blood-derived mono-
cytes are induced to Mhem by stimulation with hemoglobin– 
haptoglobin complexes and it is dependent on an autocrine action 
of secreted IL-10 (147, 148). This macrophage profile prevents 
foam cell formation and has antioxidant functions. Other study 
showed that oxPL products that accumulate in atherosclerotic 
lesions induce another phenotype designated as Mox. Data indi-
cate that Mox macrophages are characterized by high expression 
of heme oxygenase-1 and it comprises approximately 30% of all 
macrophages in established atherosclerotic lesions in experi-
mental models (149). In addition, CXCL4, a chemokine released 
by activated platelet, was demonstrated to prevent monocytes/
macrophages apoptosis and promote its differentiation into a phe-
notype called “M4” (MMP7+ S100A8+ CD68+). M4 macrophage 
was described in human coronary atherosclerotic plaques ex vivo 
and postmortem (150, 151). The prevalence of this macrophage 
subset is higher in patients with severe coronary artery disease 
and there is a significant correlation between the accumulation 
of M4 macrophages within the intima and plaque destabilization, 
which is independent of the overall number of macrophages in 
the vascular wall (150).
Recently, several groups have published that IL-17A-
stimulated macrophages are suggested to constitute a new 
macrophage population. Barin et al. (152) showed that IL-17A 
induces activation of primary macrophages in a unique profile 
of cytokines and chemokines, including IL-12p70, GM-CSF, 
IL-3, IL-9, CCL4 and CCL5, that can be distinguished from pre-
viously characterized macrophage activation states. Moreover, 
another work showed that IL-17A induces a pro-inflammatory 
transcriptome in human monocytes/macrophages, including 
cytokines such as IL-1α and IL-6, chemokines like CCL2, CCL8, 
CCL20, CXCL1, CXCL2 and CXCL6, genes involved in oxidative 
stress, upregulation of CD14, CD163 levels and downregulation 
of genes associated with T  cell costimulation. By comparing 
the entire transcriptomes of M1, M2 and M4 macrophages, 
authors confirm that IL-17A-treated macrophages are a unique 
polarization subset (153). On the other hand, it was reported 
that IL-17 also can strongly amplifies human monocytes/mac-
rophages differentiation toward M2c profile, making it resistant 
to apoptosis and promoting its MerTK-dependent clearance of 
apoptotic bodies (154). M2c cells (CD14bright CD16+ CD163+ 
MerTK+) are a subset of alternatively activated macrophages 
induced by M-CSF plus IL-10 or glucocorticoids and they are 
involved in inflammation resolution through phagocytosis of 
early apoptotic neutrophils and anti-inflammatory cytokines 
production (155). In contrast with the mentioned effects of 
IL-17, authors demonstrated that both IFN-γ/Th1 environ-
ment and IL-4-chronic exposure impair glucocorticoid and 
IL-10-induced M2c macrophage differentiation and also alters 
phagocytosis function of stablished M2c macrophages by reduc-
ing MerTK levels and promoting its apoptosis. Thus, this work 
indicates that Th17 environment orchestrates the resolution 
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of innate inflammation through expansion of M2c regulatory 
macrophages.
An important point to note is that in a predominantly Th17 
environment, monocytes/macrophages have a key role in the 
IL-17-induced inflammatory responses. In an experimental 
murine autoimmune myocarditis (EAM) model, the genetic 
ablation of IL-17RA alters the recruitment of monocytes/
macrophages, which is the most numerous component of the 
inflammatory infiltrate and it is implicated in the cardiac damage 
(152). In concordance, other work shows that IL-17A promotes 
cardiac infiltration of Ly6Chigh monocytes by inducing fibroblasts 
to produce high levels of cytokines and chemokines. Particularly, 
GM-CSF production by IL-17-stimulated cardiac fibroblasts 
drives differentiation of infiltrating monocytes into an even more 
inflammatory phenotype which further intensifies the myocardi-
tis. Experiments performed in IL17RAKO mice or depletion of 
Ly6Chigh monocytes/macrophages demonstrates the involvement 
of these innate cells in the inflammatory dilated cardiomyopathy 
(156). On the other hand, in an advanced atherosclerotic model 
in ApoEKO mice, in  vivo IL-17A blocking markedly prevents 
atherosclerotic lesion progression and improves its stability by 
reducing inflammatory burden and monocyte infiltration (153). 
Moreover, the CCL2 and CCL5 production were significantly 
reduced in those IL-17A mAb-treated mice. In vitro experiments 
demonstrated that IL-17A induces adhesion of human mono-
cytes, adhesion and rolling of platelets on endothelial cells. Other 
studies performed in early stages of atherosclerosis demonstrate 
that IL-17/IL-17RA axis has a pro-atherogenic role by promoting 
early monocyte recruitment into plaque through CCL5 produc-
tion, endothelial VCAM-1 expression and increasing CXCL1 
expression on the vessel lumen (157–159).
Purinergic Signaling
Purinergic system has been recognized as a main pathway to 
regulate immune response and it is critical to prevent the col-
lateral damage produced by the exacerbation of the immune 
response in several diseases including cardiac pathologies. In 
normal conditions, ATP is localized intracellularly where it is 
the main source of energy for cell functions and it accomplishes 
indispensable functions in cellular metabolism such as prolifera-
tion, migration, motility, biosynthesis and contraction functions 
within the cardiomyocytes. In addition to its metabolic function, 
ATP also acts as an important signaling molecule when it is 
released to the extracellular compartment. After it is released, the 
extracellular ATP hydrolysis is governed by the activity of two 
membrane ectoenzymes, the CD39 that catalyzes the phospho-
hydrolysis of ATP to ADO monophosphate (AMP) and CD73 
that hydrolyzes AMP into ADO and inorganic phosphate (45). 
CD39 and CD73 expression on immune and vascular cells and 
their enzymatic activities play decisive role in the regulation of 
the magnitude and duration of purinergic signals that modulate 
cellular function in an autocrine or paracrine manner (160). 
These effects are mediated by two types of nucleotide/nucleoside 
receptors: P1 receptors activated by extracellular ADO and P2 
receptors activated by ATP and other nucleotides such as ADP 
and AMP. The first group includes 4 ADO receptors (ADORA 1, 
ADORA 2A, ADORA 2B, and ADORA 3), and the second group 
includes several P2X and P2Y subtypes of receptors (161).
Purinergic signaling is highly described in tumoral context 
(162) and in autoimmune diseases (163) but poorly studied in 
the context of cardiac pathologies. Given the high production 
rate of ATP and the turnover required to maintain its continuous 
mechanical work, disruption of heart tissue generates the release of 
high amounts of ATP to the extracellular space. Bonner et al. have 
reported that cardiomyocytes and erythrocytes do not detectably 
express the ATP catabolic machinery, but coronary endothelial 
cells were highly positive for CD39 under basal conditions and 
a low proportion of these cells express CD73. Furthermore, 
they stated that resident cardiac APCs and monocytes were the 
responsible of the first step of ATP degradation in the heart after 
ischemic injury because they were highly positive for the CD39 
while CD73 was absent. Likewise, the dephosphorylating step of 
AMP to immunosuppressive ADO seems to take place on T lym-
phocytes and granulocytes because CD73 was mainly expressed 
in those populations (164).
In contrast to the pro-inflammatory action of ATP, ADO exhib-
its diverse immunoregulatory roles. Bonner and coworkers found 
that macrophages stimulated through ADORA 2A and ADORA 
2B receptors with ADO undergo M2 phenotype in infarcted mice. 
In addition, in CD73KO mice there was augmented expression 
of microbicidal M1 genes, while the expression of M2 genes like 
arginase-1, IL-10, and TGF-β decreased. This monocyte imbal-
ance toward inflammatory Ly6Chigh-expressing monocytes in mice 
lacking CD73 had been related to adverse myocardial healing and 
ventricular dilatation after MI (165). Furthermore, Haskó et al. 
reported that ADO diminish the oxidative burst by downregulat-
ing NO production and inhibit TNF release from monocytes and 
macrophages (166). A parallel mechanism has also been reported 
by Cain group in murine isquemia/reperfusion model where ADO 
pretreatment decreased myocardial TNF production (167). There 
is strong evidence that ADO can modulate leukocyte adhesion 
to vascular endothelium in  vivo. In this sense, Koszalka et  al. 
demonstrated that ADO is an important endogenous pathway to 
modulate the inflammatory vascular response. After a period of 
ischemia-reperfusion, they observed significant increase of leu-
kocyte adherence to the vascular endothelium only in the CD73 
mutant (168). It has also been suggested that purinergic signals 
play a role in cellular migration. Analysis of atherosclerotic lesions 
of P2Y6 KO mice revealed fewer macrophages, diminished RNA 
expression of IL-6 and VCAM-1, suggesting that deficiency in 
this ATP receptor limits atherosclerosis and plaque inflammation 
(169). Recently, it was reported that lack of P2X7 receptor resolute 
plaque destabilization by inhibiting inflammasome activation 
and consequently ameliorates experimental atherosclerosis. ATP 
binding to P2 receptors is crucial to NLRP3 assembly and the 
subsequent IL-1β release. P2X7 null mice had decreased amount 
of macrophages in the wound and, in consequence, smaller and 
less inflamed atherosclerotic lesions than respective control ani-
mals (170). Altogether, the data indicate that purinergic signaling 
can modulate macrophage polarization and infiltration; and that 
ADO is a key metabolite in suppressing inflammation following 
injury or infection.
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In addition, ADO induces the production of vascular endoth-
elial growth factor (VEGF) in human macrophages, associated 
with increased hypoxia inducible factor-1α (HIF-1α) expression, 
the main transcriptional inducer of VEGF in hypoxic milieu. 
VEGF promotes blood vessel formation, induces cell proliferation 
and initiates immune cell migration to stimulate vasculogenesis 
and angiogenesis (171). On the other hand, extracellular ATP 
contributes to tissue repair by the stimulation of P2X7 receptor 
and release of the pro-angiogenic factor VEGF (172). Summing 
up, activation of purinergic receptors in macrophages can pro-
mote wound healing and may be targeted to improve cardiac 
repair mechanisms.
Metabolism
The heart changes its substrate preferences throughout the life, 
under physiological or pathological conditions. This metabolic 
flexibility allows it to adapt to environmental changes. However, 
shifts in fuel selectivity can become detrimental in the pathologi-
cal heart (173).
Pathological cardiac hypertrophy is a common consequence of 
several cardiovascular diseases and is a maladaptive response to 
chronic stress, sometimes resulting in cardiac failure. Pathological 
hypertrophy involves a shift in fuel metabolism from fatty-acid 
oxidation to enhanced reliance on glucose. Increased glucose 
utilization is characterized by upregulation of glucose uptake 
and glycolysis concomitant with no change or a decrease in 
glucose oxidation, resulting in uncoupling of glucose uptake/
oxidation metabolism. Nowadays, it is accepted that changes in 
mitochondrial function and cardiac metabolism precede heart 
dysfunction, indicating that metabolic remodeling is an early 
event in the development of cardiac diseases.
Recent interest in understanding the impact of these funda-
mental metabolic changes on immune cell differentiation and 
function has yielded numerous studies examining the pathways 
and metabolites involved in driving protective immune responses. 
A key question that has emerged is whether differential metabolic 
activity (i.e., use of glycolysis versus mitochondrial respiration) 
is coincident with differentiation or if it is a direct driver of alterations 
in immune cell differentiation and function. Classically activated 
macrophages that promote inflammation utilize glycolysis and 
glutamine metabolism to generate large quantities of succinate 
which enhances inflammation and IL-1β production (174). 
In contrast, macrophages that play a role in tissue healing and 
inflammatory resolution increase mitochondrial lipid oxidation 
(175). A key differentiator between these metabolic phenotypes 
may arise in the mitochondria, where rather than engaging in 
conventional electron transport, altered electron flow through 
the succinate dehydrogenase complex promotes ROS generation 
and inflammation (176). Enhanced glycolysis in coronary artery 
disease patients drives mitochondrial ROS production, resulting 
in pyruvate kinase M2 (PKM2) assembly and translocation to the 
nucleus. It then phosphorylates and activates STAT3 to promote 
the production of the cytokines IL-1β and IL-6 (177). Indeed, the 
increased activation of glycolytic pathway was associated with 
epigenetic changes in monocyte-derived macrophages describing 
a new mechanism to explain trained immunity in human innate 
immune cells (178).
Diabetes is a major risk factor for cardiovascular diseases 
(179). As such it may lead to heart failure indirectly, by pro-
moting the development of coronary artery disease. However, 
it is now known that diabetes may cause heart failure also by 
eliciting a direct detrimental impact on the myocardium lead-
ing to the development of cardiac hypertrophy, diastolic and 
systolic dysfunction (180). The clinical condition associated 
with the spectrum of cardiac abnormalities induced by diabetes 
is termed diabetic cardiomyopathy. High glucose levels and 
dyslipidemia directly induce the upregulation and secretion 
of cytokines, chemokines and adhesion molecules in immune 
cells by modulating multiple signaling pathways that converge 
toward NF-κB signaling (181–183). Activation of the renin–
angiotensin–aldosterone system and accumulation of advanced 
glycation end-products (AGE) and DAMPs molecules like 
extracellular high-mobility group box-1 protein (HMGB1), also 
represent key mechanisms that mediate inflammatory response 
in the diabetic heart primarily by acting TLRs (184–186). 
Following these initial molecular events, leukocytes infiltrate 
the myocardium and perpetuate the inflammatory process 
through secretion of cytokines and pro-fibrotic factors and by 
increasing the production of ROS. Mediators resulting from this 
inflammatory cascade, in turn, modulate specific intracellular 
signaling mechanisms in cardiac cells causing hypertrophy, 
mitochondrial dysfunction, ER stress and cell death fibroblast 
proliferation and collagen production. In addition, inflamma-
tory factors may affect myocardial metabolic processes and 
interfere with cardiomyocyte contractile properties. These 
abnormalities together promote the development of diabetic 
cardiomyopathy.
Diabetes-associated metabolic derangements can directly 
induce cytokine expression and release from cardiac cells. It was 
previously shown that hyperglycemia augmented the expression 
of HMGB1 in isolated cardiomyocytes, macrophages and cardiac 
fibroblasts, thereby activating the MAPK and NF-κB pathways 
and by inducing TNF and IL-6 secretion (187). Inhibition of 
HMGB1 decreased myocardial inflammation and fibrosis in a 
murine model of type 1 diabetes and protected diabetic animals 
in response to postinfarction remodeling (187, 188).
An increase in circulating lipids may also contribute to cardiac 
inflammation in diabetes. Fatty acids activate TLR4 that strongly 
promotes inflammation through the NF-κB pathway (189). 
Mice with a TLR4 gene deletion demonstrate improved cardiac 
function and reduced cardiac intracellular lipid accumulation in 
response to streptozotocin-induced diabetes (190). Fatty acids 
induce the subsequent expression of IL-6, TNF and IL-1, which 
can be reversed by peroxisome proliferator-activated receptor-γ, 
β/δ (PPAR-b/d) (191). Previous work showed that hyperglyce-
mia and high circulating levels of lipids promote inflammation 
through the activation of protein kinase C (PKC), which activates 
MAPK pathway thereby inactivating IkB (192).
The challenge to improve cardiovascular disorders therapy by 
modulating metabolic pathways must take into account potential 
off-target effects on other cells and tissues. In these sense, by 
exploiting the intrinsic capacity of monocytes and macrophages 
to take up foreign particles, the use of nanoparticle formulations 
might be one option to achieve targeting specificity (193).
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Oxidative Stress
Oxygen is the molecular source of the production of several mol-
ecules that damage vital tissues. Reactive oxygen and nitrogen 
species (RONS) are continuously produced as by-products of the 
reaction leading to energy production through the mitochondrial 
and microsomal electron-transport chains. In phagocytes, the 
oxidative bursts and enzyme systems such as xanthine oxidase 
and cytochrome P-450 oxidase are the endogenous sources of 
RONS. While physiological levels of RONS are crucial for cell 
function, excessive RONS levels trigger oxidative stress. Oxidative 
stress may damage clues molecules (proteins, lipids, DNA) and 
could, eventually, conducted to cell death. To prevent oxidative 
stress, antioxidants have evolved to protect biological systems 
against RONS-induced damage. Oxidative stress resulting from 
uncontrolled production of RONS that exceeds the antioxidant 
capacity, exacerbate atherosclerosis; since it induces endothelial 
dysfunction by impairing the bioactivity of endothelial NO 
and promotes leukocyte adhesion, enhances inflammation and 
thrombosis.
Numerous reports demonstrated that increased oxidative 
stress is associated with disturbances in cardiovascular diseases. 
In this sense, it was reported an overproduction of superoxide 
anion by cardiac dysfunctional mitochondria or increased produc-
tion of RONS from non-mitochondrial sources in experimental 
models of type 1 diabetes (194, 195). The augmented production 
of RONS induces maladaptive cardiac response causing cardiac 
cells death contributing to cardiovascular disease (196). An 
excessive oxidative stress has been associated with increased 
cardiac cell apoptosis, as was evidenced by TUNEL+  cells and 
caspase 3 activation in T. cruzi-infected cardiac tissue (44). In 
this sense, high oxidative state has been associated with amplified 
lipid and DNA damage and the consequent cardiac cell injury 
and death. Therapeutic treatment that promotes RONS regula-
tion have been shown to be effective in reducing cardiovascular 
dysfunction.
It is known that increased oxidative stress induces modifica-
tions of LDL, generating DAMPs that are detected by TLRs on 
different immune cell populations, mainly monocytes/mac-
rophages. A variety of mechanisms mediated by enzymatic (such 
as 12/15-lipoxygenase and myeloperoxidase) or no-enzymatic 
redox reaction (such as RONS) boost LDL oxidation in the artery 
wall. The level of LDL oxidation modulates the immune system, 
when cells were treated with low oxLDL, the expression level of 
CD86, a marker for M1 macrophages, increases compared with 
that in cells treated with high oxLDL. In contrast, the expression 
level of the marker for M2 macrophages, CD206, significantly 
increases in cells treated with high oxLDL compared with that 
in cells treated with native LDL or low oxLDL. These results 
indicate that the degree of LDL oxidation affects the differentia-
tion of monocytes into different subtypes of macrophages (197). 
Further research is needed to assess the functional consequences 
of oxidation processes on human macrophage behavior.
CONCLUSiON AND PeRSPeCTiveS
The crucial role of mononuclear phagocyte system in homeostasis 
and inflammation described herein makes it a potential therape-
utic target for a variety of cardiovascular diseases. However, most 
of our current knowledge on monocyte/macrophage phenotypes 
and functions is derived from studies performed in murine 
models and, as such, requires clinical translation and validation 
in human cells. Understanding macrophage activation in such 
settings using high-resolution, single-cell and deep phenotyp-
ing approaches will provide the basis for therapeutic proposals 
directed to target specific subsets while sparing others.
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